This is a window opportunity study of propranolol in patients with angiosarcoma. The aim of
this study is to prospectively evaluate the activity of propranolol in the clinical setting
as monotherapy, where the neoadjuvant setting provides a good opportunity to rapidly evaluate
both the clinical response and histological response, without a significant delay in
anti-cancer treatment.